Document is current
Any future updates will be listed below
-
Authors
Demirci Yildirim, Tuba https://orcid.org/0000-0003-3186-0591
Kahraman, Aslı https://orcid.org/0000-0001-5781-8506
Köken Avşar, Aydan https://orcid.org/0000-0003-4149-621X
Onen, Fatos https://orcid.org/0000-0002-6341-2622
Akar, Servet https://orcid.org/0000-0002-3734-1242
Sari, İsmail https://orcid.org/0000-0001-7737-4180
-
Funding
Funding for this research was provided by:
Pfizer (ID#68022735)
- License Information
-
More Information
Article History
Received: 11 June 2023
Accepted: 2 August 2023
First Online: 10 August 2023
Declarations
:
: The authors report no conflicts of interest.
: The study was conducted in accordance with the Helsinki Declaration and was approved by the local ethics committee (IRB number: 0166). Written informed consent was obtained from all participants. It was also registered on clinicaltrials.gov with the number NCT04792957.
: The authors declare that the submitted work is their own and that copyright has not been breached in seeking its publication. This study was presented as an oral presentation during the EULAR 2022 European Congress of Rheumatology, held from June 1–4, 2022, in Denmark.
